Evidence map›Paper›PMID 41126910›Full record

ArticleThe Lancet regional health. Europe2025

Estimated effect of reduced asymptomatic testing on missed

Lotte Werner, Vita W Jongen, Sylvia M Bruisten, Maarten F Schim van der Loeff, Elske Hoornenborg, Henry J C de Vries, Janneke C M Heijne

Abstract read
In one paragraph

Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lotte WernerDepartment of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands.
Vita W JongenDepartment of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands.
Sylvia M BruistenDepartment of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands.
Maarten F Schim van der LoeffDepartment of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands.
Elske HoornenborgDepartment of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands.
Henry J C de VriesDepartment of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands.
Janneke C M HeijneDepartment of Infectious Diseases, Public Health Service Amsterdam, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Widespread testing for asymptomatic chlamydia is under debate. In the Netherlands, from 2025, Methods: We included consultations of women and heterosexual men (≥16 years) tested for CT at the CSH Amsterdam, the Netherlands, 2015-2023. We assessed consultations where no test would have been performed under the new guideline (neither symptoms nor notified), including CT diagnosed during those consultations (=undetected CT). Determinants of undetected CT were assessed using multivariable logistic regression with cluster-robust standard errors. Analyses were stratified by age (<25/≥25 years) and gender (women/men). Findings: In total 241,005 consultations among 124,527 individuals were analysed. Under the new guideline, CT testing would not have been performed in 167,476 (69.5%, 95% confidence interval [CI]; 69.3-69.7%) consultations; mostly among women <25 years (n = 100,756/167,476, 60.2%). In total 17,771/32,360 (54.9%, 95% CI; 54.4-55.5%) CT cases would have remained undetected and untreated: 12,092 among women <25 years, 1498 among women ≥25 years, 3428 among men <25 years, and 753 among men ≥25 years. Determinants of undetected CT were younger age, no/primary/secondary education, and recent bacterial STI. Interpretation: The new guideline limiting CT testing might lead to a more than twofold reduction in diagnoses and antibiotic prescriptions in women and heterosexual men. Surveillance of STIs and associated complications is essential to monitor unintended consequences of the guideline change. Funding: None.

Indexed as

Asymptomatic chlamydia infectionsAsymptomatic sexually transmitted infection testingChlamydia controlChlamydia trachomatisRetrospective observational study

Identifiers

PMID41126910
PMCPMC12537342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.